Olgu Sunumu
PDF Mendeley EndNote BibTex Kaynak Göster

Yıl 2021, Cilt 12, Sayı 1, 7 - 11, 18.03.2021
https://doi.org/10.33706/jemcr.816161

Öz

Kaynakça

  • 1. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. PubMed PMID: 32350134; PubMed Central PMCID: PMCPMC7245089.
  • 2. Zu ZY, Jiang MD, Xu PP, et al. Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology. 2020 Aug;296(2):E15-E25. doi: 10.1148/radiol.2020200490. PubMed PMID: 32083985; PubMed Central PMCID: PMCPMC7233368.
  • 3. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248. PubMed PMID: 32161940; PubMed Central PMCID: PMCPMC7108125.
  • 4. Salmon JH, Perotin JM, Morel J, et al. Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data. Rheumatology (Oxford, England). 2018 Jan 1;57(1):134-139. doi: 10.1093/rheumatology/kex403. PubMed PMID: 29069471; eng.
  • 5. Worm M, Eckermann O, Dolle S, et al. Triggers and treatment of anaphylaxis: an analysis of 4,000 cases from Germany, Austria and Switzerland. Dtsch Arztebl Int. 2014 May 23;111(21):367-75. doi: 10.3238/arztebl.2014.0367. PubMed PMID: 24939374; PubMed Central PMCID: PMCPMC4075276.
  • 6. Park EH, Lee EY, Shin K, et al. Tocilizumab-induced anaphylaxis in patients with adult-onset Still's disease and systemic juvenile idiopathic arthritis: a case-based review. Rheumatology international. 2020 May;40(5):791-798. doi: 10.1007/s00296-019-04456-9. PubMed PMID: 31598752.
  • 7. Salmon JH, Perotin JM, Morel J, et al. Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data. Rheumatology (Oxford, England). 2018 Jan 1;57(1):134-139. doi: 10.1093/rheumatology/kex403. PubMed PMID: 29069471.
  • 8. Tetu P, Hamelin A, Moguelet P, et al. Management of hypersensitivity reactions to Tocilizumab. Clin Exp Allergy. 2018 Jun;48(6):749-752. doi: 10.1111/cea.13142. PubMed PMID: 29603809.
  • 9. Yasuoka R, Iwata N, Abe N, et al. Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis. Mod Rheumatol. 2019 Mar;29(2):324-327. doi: 10.1080/14397595.2018.1457490. PubMed PMID: 29578355.
  • 10. Galvao VR, Castells MC. Hypersensitivity to biological agents-updated diagnosis, management, and treatment. J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):175-85; quiz 186. doi: 10.1016/j.jaip.2014.12.006. PubMed PMID: 25754718.

Tocilizumab‑induced anaphylaxis in two patients with COVID‐19‐induced cytokine storm

Yıl 2021, Cilt 12, Sayı 1, 7 - 11, 18.03.2021
https://doi.org/10.33706/jemcr.816161

Öz

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a zoonotic virus which was first discovered in Wuhan, the People’s Republic of China in December 2019 and has led to one of the greatest pandemics of world history in a short period of time. SARS-CoV-2 is a rapidly spreading infectious disease with a high mortality rate. The disease has a moderate and severe course in approximately 20% of the patients and mortality reaches up to 62% among these patients . The majority of the patients develop SARS-CoV-2-induced pneumonia and manifestations of pneumonia rapidly progress to respiratory failure. The treatment of COVID‐19‐induced cytokine storm is not definitive, several pharmacological agents have been tried and used. Tocilizumab (TCZ) is a promising agent that is used for the treatment of cytokine storm. TCZ is an IgG1 class recombinant humanized monoclonal antibody against interleukin-6 (IL-6) receptor [4].However, potential IgE-mediated immunological reactions against this drug, especially anaphylaxis, may deprive these patients of an important treatment option for the treatment of COVID-19-induced cytokine storm. Although TCZ-induced anaphylaxis has been reported in the literature as case reports of indicated rheumatic diseases, TCZ-induced anaphylaxis has not yet been reported in patients using TCZ for PCR positive COVID‐19‐induced cytokine storms. In this case series, we aimed to represent cases of anaphylaxis which developed in two different patients using TCZ for COVID-19-induced cytokine storm.

Kaynakça

  • 1. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. PubMed PMID: 32350134; PubMed Central PMCID: PMCPMC7245089.
  • 2. Zu ZY, Jiang MD, Xu PP, et al. Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology. 2020 Aug;296(2):E15-E25. doi: 10.1148/radiol.2020200490. PubMed PMID: 32083985; PubMed Central PMCID: PMCPMC7233368.
  • 3. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248. PubMed PMID: 32161940; PubMed Central PMCID: PMCPMC7108125.
  • 4. Salmon JH, Perotin JM, Morel J, et al. Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data. Rheumatology (Oxford, England). 2018 Jan 1;57(1):134-139. doi: 10.1093/rheumatology/kex403. PubMed PMID: 29069471; eng.
  • 5. Worm M, Eckermann O, Dolle S, et al. Triggers and treatment of anaphylaxis: an analysis of 4,000 cases from Germany, Austria and Switzerland. Dtsch Arztebl Int. 2014 May 23;111(21):367-75. doi: 10.3238/arztebl.2014.0367. PubMed PMID: 24939374; PubMed Central PMCID: PMCPMC4075276.
  • 6. Park EH, Lee EY, Shin K, et al. Tocilizumab-induced anaphylaxis in patients with adult-onset Still's disease and systemic juvenile idiopathic arthritis: a case-based review. Rheumatology international. 2020 May;40(5):791-798. doi: 10.1007/s00296-019-04456-9. PubMed PMID: 31598752.
  • 7. Salmon JH, Perotin JM, Morel J, et al. Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data. Rheumatology (Oxford, England). 2018 Jan 1;57(1):134-139. doi: 10.1093/rheumatology/kex403. PubMed PMID: 29069471.
  • 8. Tetu P, Hamelin A, Moguelet P, et al. Management of hypersensitivity reactions to Tocilizumab. Clin Exp Allergy. 2018 Jun;48(6):749-752. doi: 10.1111/cea.13142. PubMed PMID: 29603809.
  • 9. Yasuoka R, Iwata N, Abe N, et al. Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis. Mod Rheumatol. 2019 Mar;29(2):324-327. doi: 10.1080/14397595.2018.1457490. PubMed PMID: 29578355.
  • 10. Galvao VR, Castells MC. Hypersensitivity to biological agents-updated diagnosis, management, and treatment. J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):175-85; quiz 186. doi: 10.1016/j.jaip.2014.12.006. PubMed PMID: 25754718.

Ayrıntılar

Birincil Dil İngilizce
Konular Tıp
Bölüm Case Report
Yazarlar

Emel ATAYIK (Sorumlu Yazar)
Konya Training and Research Hospital Department of Allergy and Clinical Immunology, Konya, Turkey
0000-0002-7011-7752
Türkiye


Gökhan AYTEKİN
Konya Training and Research Hospital Department of Allergy and Clinical Immunology, Konya, Turkey
0000-0002-9089-5914
Türkiye

Destekleyen Kurum YOK
Yayımlanma Tarihi 18 Mart 2021
Yayınlandığı Sayı Yıl 2021, Cilt 12, Sayı 1

Kaynak Göster

Bibtex @olgu sunumu { jemcr816161, journal = {Journal of Emergency Medicine Case Reports}, eissn = {2149-9934}, address = {Yukarı Ayrancı Güleryüz Sk. No: 26/19 06550 Çankaya-Ankara, Turkey}, publisher = {Acil Tıp Uzmanları Derneği}, year = {2021}, volume = {12}, number = {1}, pages = {7 - 11}, doi = {10.33706/jemcr.816161}, title = {Tocilizumab‑induced anaphylaxis in two patients with COVID‐19‐induced cytokine storm}, key = {cite}, author = {Atayık, Emel and Aytekin, Gökhan} }
APA Atayık, E. & Aytekin, G. (2021). Tocilizumab‑induced anaphylaxis in two patients with COVID‐19‐induced cytokine storm . Journal of Emergency Medicine Case Reports , 12 (1) , 7-11 . DOI: 10.33706/jemcr.816161
MLA Atayık, E. , Aytekin, G. "Tocilizumab‑induced anaphylaxis in two patients with COVID‐19‐induced cytokine storm" . Journal of Emergency Medicine Case Reports 12 (2021 ): 7-11 <https://dergipark.org.tr/tr/pub/jemcr/issue/60732/816161>
Chicago Atayık, E. , Aytekin, G. "Tocilizumab‑induced anaphylaxis in two patients with COVID‐19‐induced cytokine storm". Journal of Emergency Medicine Case Reports 12 (2021 ): 7-11
RIS TY - JOUR T1 - Tocilizumab‑induced anaphylaxis in two patients with COVID‐19‐induced cytokine storm AU - Emel Atayık , Gökhan Aytekin Y1 - 2021 PY - 2021 N1 - doi: 10.33706/jemcr.816161 DO - 10.33706/jemcr.816161 T2 - Journal of Emergency Medicine Case Reports JF - Journal JO - JOR SP - 7 EP - 11 VL - 12 IS - 1 SN - -2149-9934 M3 - doi: 10.33706/jemcr.816161 UR - https://doi.org/10.33706/jemcr.816161 Y2 - 2020 ER -
EndNote %0 Journal of Emergency Medicine Case Reports Tocilizumab‑induced anaphylaxis in two patients with COVID‐19‐induced cytokine storm %A Emel Atayık , Gökhan Aytekin %T Tocilizumab‑induced anaphylaxis in two patients with COVID‐19‐induced cytokine storm %D 2021 %J Journal of Emergency Medicine Case Reports %P -2149-9934 %V 12 %N 1 %R doi: 10.33706/jemcr.816161 %U 10.33706/jemcr.816161
ISNAD Atayık, Emel , Aytekin, Gökhan . "Tocilizumab‑induced anaphylaxis in two patients with COVID‐19‐induced cytokine storm". Journal of Emergency Medicine Case Reports 12 / 1 (Mart 2021): 7-11 . https://doi.org/10.33706/jemcr.816161
AMA Atayık E. , Aytekin G. Tocilizumab‑induced anaphylaxis in two patients with COVID‐19‐induced cytokine storm. Journal of Emergency Medicine Case Reports. 2021; 12(1): 7-11.
Vancouver Atayık E. , Aytekin G. Tocilizumab‑induced anaphylaxis in two patients with COVID‐19‐induced cytokine storm. Journal of Emergency Medicine Case Reports. 2021; 12(1): 7-11.
IEEE E. Atayık ve G. Aytekin , "Tocilizumab‑induced anaphylaxis in two patients with COVID‐19‐induced cytokine storm", Journal of Emergency Medicine Case Reports, c. 12, sayı. 1, ss. 7-11, Mar. 2021, doi:10.33706/jemcr.816161